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Letters to the Editor
1056Reply to: ‘‘Pre-therapeutic dosimetry evaluation and
selective internal radiation therapy of hepatocellular
carcinoma using yttrium-90-loaded microspheres’’To the Editor:
We have read with interest the comments made by Garin et al. to
our recently published review on yttrium-90 radioembolization
(RE) for hepatocellular carcinoma (HCC) [1]. Yet, while they raise
relevant questions regarding the dosimetric approach to RE using
yttrium-90 microspheres, they also convey erroneous messages
regarding pretended advantages of glass vs. resin microspheres
that should be clariﬁed.
We never claimed that no correlation exists between the dis-
tribution of radiolabeled macroaggregated albumin (MAA) and
therapeutic microspheres. The referred study by Knesaureck
et al. shows that when such correlation between MAA and resin
microspheres was analyzed, it ranged from high to very poor,
and the average correlation was not the ideal one. A more recent
study by the same group indicates that differences in catheter tip
position are likely to be the main contributor to this mismatch
[2]. No study has been done with glass microspheres so unless
Garin et al. may provide additional data, there is no evidence to
suggest that a better correlation exists for glass microspheres.
In any case, these sorts of data have to be considered cautiously
since the actual distribution of beta radiation cannot be accu-
rately quantiﬁed in vivo after RE.
Furthermore, we made it clear that the MAA scan could be
used to anticipate the average dose of radiation that can be deliv-
ered to tumor areas. The statement made by Garin et al. that MAA
only predicts response when using glass microspheres is
unfounded and it can be misleading for the inexperienced reader.
Several retrospective studies have shown that unsurprisingly, the
average dose received by tumors was higher for those that
showed an objective response after therapy, both for resin [3,4]
and for glass microspheres [5,6]. Nevertheless, a signiﬁcant over-
lap was also observed and a consistent cut-off value has not been
reported. For glass microspheres, proposed thresholds for aimed
tumor absorbed doses range from 205 Gy in the Rennes series
[5] to 500 Gy in the Milano series [6]. According to the manufac-
turer’s instructions, the prescribed activity of glass microspheres
is based on a 2-compartment dosimetry model with the aim of
delivering a radiation dose of 120 Gy to the targeted liver (irre-
spective of the tumor burden). For resin microspheres, users have
to choose between an empiric formula based on body surface
area and tumor burden, or by a 3-compartment dosimetry model
with the aim of delivering a radiation dose of 70–80 Gy to the tar-Journal of Hepatology 20geted non-tumoral liver. However, experienced centers have
described different attempts to use other dosimetry models to
improve the efﬁcacy of RE with both resin [7] and glass micro-
spheres [8]. The statement that the dosimetry approach devel-
oped by Garin et al. resulted in treatment intensiﬁcation in 25%
of patients, along with good tolerance has to be taken with cau-
tion since it is based on only 4 patients that received a dose
higher than that prescribed by the conventional method of activ-
ity calculation for glass microspheres [5]. This early experience
from their and other groups with these dosimetry models is cer-
tainly encouraging but only prospective studies in large series of
patients will tell us if this approach proves to preserve safety
while they increase efﬁcacy.
It is well know that with a comparable size range but a differ-
ent activity per sphere, the number of particles used in a typical
RE treatment is higher for resin than for glass microspheres.
Garin et al. invalidly derive from this fact that resin microspheres
are associated with a higher embolic effect and a higher chance of
intrahepatic reﬂux without providing any scientiﬁc support to
these assertions. Furthermore, they sustain that resin micro-
spheres carry an increased risk of gastric ulcer, which again is a
misleading statement. Gastric ulcers result from the unnoticed
presence of collateral vessels and therefore, they are much
dependent on the experience of the interventional radiologist
performing the procedure and on the site of injection. The higher
number of studies reporting gastric ulcers after RE using resin
microspheres is most likely due to the fact that glass micro-
spheres are almost invariably delivered by a selective lobar or
sublobar injection while resin microspheres are quite often
injected into the proper hepatic artery (particularly for unresec-
table liver metastases). When glass microspheres were injected
into the hepatic artery in an early series of HCC patients, 13.6%
of them developed gastric ulcerations [9]. For resin microspheres,
in the study referenced by Garin et al., the Mount Sinai group
reported an incidence of 2.6% among 270 RE-treated patients
[10].
Finally, Garin et al. conclusion that ‘‘resin and glass micro-
spheres are different products, with differing efﬁcacy and toxicity
proﬁles’’ is against all available scientiﬁc evidence. As shown in
Fig. 5 of our review, the overall survival of patients treated with
glass or resin microspheres across the different HCC tumor stages
is very consistent. The incidence of liver-related adverse events
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shown in Table 3 is also very similar despite the above-men-
tioned differences in the proportion of patients treated in a lobar
fashion.
In summary, we totally agree with Garin et al. that better
dosimetry models for therapeutic planning will be welcomed
and their development is warranted, but we respectfully disagree
that they are crucial, since the currently used methods result in
signiﬁcant clinical activity with an acceptable incidence of liver
toxicity. Most importantly, we cannot ﬁnd any scientiﬁc basis
to sustain that glass microspheres have substantial beneﬁts over
resin microspheres or vice versa. What the available evidence
shows is that radioembolization is indeed a very consistent
therapeutic procedure irrespective of the device used and the
type of tumor treated, and that future efforts should be dedicated
to improve their performance and to ﬁnd the precise role it may
play in the evolving treatment paradigm of primary and second-
ary liver tumors.
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Identiﬁcation of chronic hepatitis B
To the Editor:
Onepaperwith impressiveﬁndings recently published in The Jour-
nal of Hepatology by Veldhuijzen et al., reported that on-site testing
could increase thedetecting rateofhepatitisB forhigh-riskpersons
[1].Wewould like to comment that Veldhuijzen et al.’s paper high-
lights the concept that only thosewho know they are infectedwith
hepatitis B could have the chance to receive antiviral treatment.
Likewise, Hsu et al.’s study showed that using electronic health
records among primary care providers could signiﬁcantly increase
the screening rate of hepatitis B for high-risk persons [2]. Li et al.
reported that those having a family physician and having better
knowledge of hepatitis B could be associated with increased
screening rates of hepatitis B [3]. These studies provide valuable
evidence that hepatitis B screening recommended by primary care
providers could increase the detecting rate of hepatitis B.
Taiwan is the ﬁrst country in the world to a commence
national hepatitis B immunization program for newborns.
Initially, hepatitis B vaccine was only given to newborns whose
mothers were hepatitis B carriers since July 1984. Two years
later, universal immunization has been extended to all newborns
from 1986 to date [4]. Since the prevalence of hepatitis B carriers
was around 14.7–19.5% in Taiwan before universal immunization
[5,6], and the current CDC guidelines already recommend screen-
ing of all subjects born in countries with hepatitis B prevalence
P2% [7], based on cost-beneﬁt effect, we would like to suggest
that migrants who were born in Taiwan before 1986 should be
recommended for hepatitis B screening.
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